Pfizer Vaccine Gets Approval of DRAP for Use in Pakistan

A COVID-19 vaccine made by Pfizer has been issued by the Pakistan Drug Regulatory Authority (DRAP).

The details indicate that the immuno-compromised population will receive Pfizer's COVID-19 vaccine as a priority, as European and Chinese vaccines are not suitable for people living with underlying health issues.

The sixth vaccination to be used in the country for DRAP is Pfizer's COVID-19 vaccine. Three Chinese Sinopharm, Cansino and Sinovac vaccines have already been licenced by DRAP. The other two DRAP-approved vaccines are Sputnik V from Russia and AstraZeneca AZD1222.

Last week Pakistan received a worldwide initiative, COVAX, to provide equitable access to GAVI-led COVID-19 vaccines, with its first shipment of 106,000 Pfizer mRNA vaccines.

The vaccination of Pfizer is kept at -70 °C. In 23 ultra-cold chain (UCC) refrigerators across the country, the Pfizer vaccine acquired by COVAX was stored.

The Pfizer 2-dose vaccine is 95% effective for preventing COVID-19 infections in non-prior infections.

Moreover, Pakistan also buys directly from New York-based pharmaceuticals companies 1 million doses of Pfizer's COVID-19 vaccine.

In July or August, the first lot of Pfizer's directly acquired vaccine will enter the country.